secwatch.observer — SEC 8-K summary
======================================

Issuer:     Skye Bioscience, Inc. (SKYE)
CIK:        0001516551
Form:       8-K
Filed at:   2026-02-02T23:59:59+00:00
Accession:  0001628280-26-004451
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Skye Bioscience reports 52-week weight loss of 22.3% for nimacimab+semaglutide combo; no plateau observed
--------------------------------------------------------------------------------

- Nimacimab 200mg + semaglutide 2.4mg achieved 22.3% mean weight loss at 52 weeks; no plateau observed, suggesting further efficacy potential.
- Weight regain at 13-week off-therapy follow-up was 17.8% for combo vs 37.3% for semaglutide alone, a >50% reduction in rebound.
- No serious adverse events or AESIs reported during 52-week extension; safety profile maintained.
- Full topline Phase 2a extension data expected in Q3 2026; cash runway into Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1516551/000162828026004451/0001628280-26-004451-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1516551/000162828026004451/skye-20260202.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-004451

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer